NASDAQ:LIAN

LianBio (LIAN) Stock Forecast, Price & News

$1.50

0.00 (0.00%)

(As of 10:39 AM ET)

Compare

Today's Range: $1.46
▼
$1.56
50-Day Range: $1.50
▼
$2.23
52-Week Range: $1.07
▼
$2.90

Volume: 43,980 shs
Average Volume: 221,621 shs
Market Capitalization: $160.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

LianBio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 900.0% Upside
$15.00 Price Target
Short Interest: Healthy
0.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.95) to ($1.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

685th out of 963 stocks

Pharmaceutical Preparations Industry

313th out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
LianBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, LianBio has a forecasted upside of 900.0% from its current price of $1.50.
Amount of Analyst Coverage
LianBio has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.21% of the float of LianBio has been sold short.
Short Interest Ratio / Days to Cover
LianBio has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in LianBio has recently increased by 38.15%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
LianBio does not currently pay a dividend.
Dividend Growth
LianBio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIAN.

3.3

News and Social Media Coverage

News Sentiment
LianBio has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for LianBio this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LIAN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added LianBio to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LianBio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.59% of the stock of LianBio is held by insiders.
Percentage Held by Institutions
74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for LianBio are expected to decrease in the coming year, from ($0.95) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LianBio is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LianBio is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
LianBio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About LianBio (NASDAQ:LIAN) Stock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LIAN Price History

30 days | 90 days | 365 days | Advanced Chart

LIAN Stock News Headlines

September 8, 2023 | finance.yahoo.com

We're Not Very Worried About LianBio's (NASDAQ:LIAN) Cash Burn Rate

August 28, 2023 | finance.yahoo.com

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 14, 2023 | finance.yahoo.com

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 3, 2023 | finance.yahoo.com

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

July 29, 2023 | finance.yahoo.com

Institutions own 21% of LianBio (NASDAQ:LIAN) shares but private equity firms control 54% of the company

July 27, 2023 | finance.yahoo.com

LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

July 18, 2023 | finance.yahoo.com

LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

July 17, 2023 | finance.yahoo.com

LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

July 12, 2023 | finance.yahoo.com

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

June 26, 2023 | finance.yahoo.com

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

June 12, 2023 | realmoney.thestreet.com

2 Stocks I'm Watching in a Market Supported by FOMO and Short Squeezes

June 8, 2023 | finance.yahoo.com

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

June 8, 2023 | marketwatch.com

ADRs End Mostly Lower, Oatly and LianBio Trade Actively

June 6, 2023 | finance.yahoo.com

LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China

June 1, 2023 | finance.yahoo.com

LianBio to Participate in Upcoming Investor Conferences

May 11, 2023 | finance.yahoo.com

LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China

April 27, 2023 | realmoney.thestreet.com

Is This Just an Oversold Bounce? Let's Take What We Can Get

April 27, 2023 | marketwatch.com

LianBio Shares Rise 11% After Positive Mavacamtem Trial Results

April 27, 2023 | marketwatch.com

ADRs End Mostly Lower, Dassault Systemes, LianBio Trade Actively

April 21, 2023 | marketwatch.com

LianBio Gets China Approval for Priority Review of Mavacamten New Drug App

April 21, 2023 | finance.yahoo.com

LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy

April 21, 2023 | finance.yahoo.com

LianBio Promotes Pascal Qian to Chief Commercial Officer

March 29, 2023 | markets.businessinsider.com

Raymond James Sticks to Its Buy Rating for LianBio Sponsored ADR (LIAN)

March 27, 2023 | finance.yahoo.com

LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

See More Headlines

Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

LIAN Company Calendar

Last Earnings: 8/14/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LIAN
CUSIP: N/A
CIK: 1831283
Web: www.lianbio.com
Phone: 609-486-2308
Fax: N/A
Employees: 163
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +900.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-110,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.38%
Return on Assets: -27.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.62
Quick Ratio: 12.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.71 per share
Price / Book: 0.55

Miscellaneous

Outstanding Shares: 107,170,000
Free Float: 99,034,000
Market Cap: $160.76 million
Optionable: Not Optionable
Beta: 0.59

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Konstantin Poukalov (Age 39)
Founder & Exec. Chairman

Dr. Yizhe Wang Ph.D. (Age 53)
CEO & Director
Comp: $1.34M

Ms. Yi Larson M.B.A. (Age 43)
CFO & Treasurer
Comp: $1.41M

Ms. Brianne Jahn (Age 37)
Chief Bus. Officer

Mr. Jiang Qian (Age 54)
Chief Commercial Officer & GM of China

Dr. Michael Humphries M.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LIAN Stock - Frequently Asked Questions

Should I buy or sell LianBio stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIAN shares.
View LIAN analyst ratings or view top-rated stocks.
What is LianBio's stock price forecast for 2023?: 1 analysts have issued 1 year price objectives for LianBio's shares. Their LIAN share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for LIAN or view top-rated stocks among Wall Street analysts.
How have LIAN shares performed in 2023?: LianBio's stock was trading at $1.64 at the beginning of 2023. Since then, LIAN stock has decreased by 8.5% and is now trading at $1.50.
View the best growth stocks for 2023 here.
When is LianBio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LIAN earnings forecast.
How were LianBio's earnings last quarter?: LianBio (NASDAQ:LIAN) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07.
What ETF holds LianBio's stock ?: Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio.

When did LianBio IPO?: (LIAN) raised $325 million in an initial public offering on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO.
What is LianBio's stock symbol?: LianBio trades on the NASDAQ under the ticker symbol "LIAN."
Who are LianBio's major shareholders?: LianBio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.93%), Affinity Asset Advisors LLC (0.75%), Citigroup Inc. (0.66%), Renaissance Technologies LLC (0.29%), Acadian Asset Management LLC (0.13%) and MYDA Advisors LLC (0.13%).
View institutional ownership trends.
How do I buy shares of LianBio?: Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is LianBio's stock price today?: One share of LIAN stock can currently be purchased for approximately $1.50.
How much money does LianBio make?: LianBio (NASDAQ:LIAN) has a market capitalization of $160.76 million. The company earns $-110,290,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.
How many employees does LianBio have?: The company employs 163 workers across the globe.
How can I contact LianBio?: The official website for the company is www.lianbio.com. The company can be reached via phone at 609-486-2308 or via email at ir@lianbio.com.

This page (NASDAQ:LIAN) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial